Electromed, Inc. (ELMD) Earnings Call Transcript & Summary
August 25, 2026
Earnings Call Speaker Segments
Mike Cavanaugh
executiveGood afternoon, everyone, and thanks for being on the Electromed earnings call. Financial results for the fourth quarter of fiscal 2026 were issued by Electromed Inc. earlier today. You can find that press release right now on the company's website, www.smartvest.com. Prior to beginning, I want to remind all of you that certain statements management makes during this call are viewed as forward-looking statements, which include statements regarding the company's future operating and financial results and plans. Risks and uncertainties apply to such statements, and those could lead to actual performance or achievements differing materially from what was projected. Expectations of management as of today's date are represented by any such statements. Undue reliance should not be placed on those forward-looking statements, and no obligation is undertaken by the company to update or revise forward-looking statements, whether as a result of new information, future events or otherwise. For additional guidance on this matter, please refer to the company's SEC filings. On the call with me today are Jim Cunniff, Electromed's President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer. As was done on previous calls, operational highlights from the quarter will be provided by Jim. The financials will then be reviewed by Brad, and a question-and-answer session will close things out. With that, I'll now hand the call over to Jim Cunniff, President and Chief Executive Officer of Electromed.
Jim Cunniff
executiveThanks, Mike, and I appreciate everyone being here with us today. It's my pleasure to share results from yet another record-setting quarter at Electromed. During Q4, we achieved our 15th quarter in a row where both revenue and profit increased compared with the same period a year earlier — a performance history that speaks to how durable our direct-to-patient approach is, and to the rising awareness of SmartVest among those living with bronchiectasis. Fourth-quarter net revenue reached a record $19.4 million, which is 12% higher than the fourth quarter a year ago. Once again, we generated operating leverage during the quarter. Operating income came in at $3.8 million in Q4, which works out to 26% growth compared with last year. On a fully diluted basis, earnings per share hit $0.39, also a quarterly record. Our core home care channel drove growth this quarter, expanding 15%, while our distributor channel rose 2% — both showing steady demand for SmartVest. Hospital revenue fell 29% during the quarter. As we've noted on earlier calls, hospital orders take longer to close and are far less predictable than what we see in our other channels. We remain bullish on hospitals as a gateway into the home, and we'll keep investing in this part of our business. We finished the quarter with 64 direct sales representatives, which is 6 more reps than we had in the third quarter; that gain reflects hiring done ahead of territory expansions we've planned for fiscal 2027, and we're happy with the quality of talent we've managed to add to the team. Our sales force continues to grow in a deliberate way, and I remain impressed by the revenue growth this team has produced. As most of you are aware, the biggest strategic opportunity for Electromed sits within the underserved bronchiectasis market. Right now, roughly 1 million patients across the United States have a bronchiectasis diagnosis, but only around 16% of them are presently getting the benefit of high-frequency chest wall oscillation therapy. That means roughly 800,000 patients who carry a bronchiectasis diagnosis could benefit from SmartVest yet have never been prescribed therapy. We further estimate that over 4 million more individuals might have bronchiectasis that hasn't been diagnosed, which highlights both the market opportunity and the need for additional education among patients and providers. To tackle this, we launched our triple down on bronchiectasis campaign last year, aiming to boost awareness of our therapy and spotlight how essential airway clearance is when treating bronchiectasis. The campaign centers on our 3-part treatment approach. First, clear airways first with SmartVest to remove the mucus that feeds future infections; second, treat the infection with antibiotics; and third, reduce inflammation. Taken together, these 3 steps are meant to interrupt the cycle of chronic infection, persistent inflammation and airway damage that fuels progressive lung disease and a declining quality of life for these patients. This year, we've broadened the campaign through a new initiative called Treat Smart from the start, which is intended to help clinicians spot patients whose existing airway clearance therapy isn't working and figure out whether it's time to reassess treatment. In addition to those initiatives, our clinical group stayed busy this quarter building awareness with providers. We had a presence at two respiratory conferences held regionally, where together we connected with over 200 clinicians. We also ran three webinars connecting peers this quarter, and every one of them drew no fewer than 100 clinicians, plus we showed up at a number of national conferences. Turning to research, we finished a manuscript that got accepted to appear in the September edition of the COPD Foundation Journal. Drawing on information from the NTM Bronchiectasis Research Registry, the paper showed that 58% of patients who qualified went without HFCWO therapy even though they satisfied every clinical criterion required for insurance coverage. That gap matters, and we're tackling it by working with physicians who see large numbers of bronchiectasis diagnoses yet haven't started prescribing HFCWO therapy. On a separate note, the BE NTM Association rolled out a fresh educational site aimed at physicians and patients, featuring a quick guide to airway clearance. We take pride in sponsoring their airway clearance resource library, which helps fill the gap in education for patients and providers. I've mentioned before our smart order e-prescribe solution, and it's transforming the way prescribing clinics send orders to our fulfillment team with greater efficiency. Notably, the Centers for Medicare and Medicaid Services has now finalized its administrative simplification rule, which adopts new standards covering health care claims attachment transactions along with electronic signatures. What that means practically is that covered entities must update the way they handle orders and stop using faxes by May of 2028. Our e-prescribed solution is already compliant with CMS' requirements for electronic signatures and order processing, so we're well positioned as the industry transitions away from faxes. During the fourth quarter, Smart Order accounted for over 45% of the orders we got, and those shipments went out on average 5 days quicker than ones sent by fax. Broadening payer coverage stays among our core strategies, since it's ultimately what provides patients in need with access to SmartVest; we closed the year with 87% of covered lives in the United States under contract. That's a huge achievement for our market access team, which wrapped up the year having signed 40 new payer contracts and grown our network by over 6 million covered lives. Another point of pride is that Electromed's products are made right here in the United States. With all the supply chain turmoil the industry has experienced, we see our U.S.-based operations as an edge over competitors. 99% of our net revenue comes from domestic sources, and that concentration reassures us about sustaining our solid history of on-time delivery along with gross margins of mid-70% or better. I'd also like to acknowledge the Electromed team, which keeps performing at a high level. Not long ago, the Minneapolis St. Paul Business Journal ranked Electromed the eighth fastest-growing public company in Minnesota, and the Star Tribune named us a top workplace in Minnesota this year. In fiscal 2026, 45% of our new hires arrived via employee referrals. The people on our team are committed and eager to recruit others who share those same qualities. Our view is that when staff are engaged, that carries through to engaged customers, and this positive loop played a major role in the way this company was constructed. Before handing things to Brad, I want to spend a moment discussing a significant leadership change we announced earlier today. Following a great deal of reflection and conversation with our Board, I've made the choice to step down from my role as Chief Executive Officer of Electromed, with the expected date falling in April 2027. Alongside this decision comes a careful succession planning effort guided by our Board, and my sense is that the timing works well both for the business and for me on a personal level. I take enormous pride in everything our team has achieved across the last 3 years. Together we've constructed a solid enterprise, put in place a distinct growth strategy and, most crucially, assembled a gifted leadership group that leaves me deeply assured about what lies ahead for this company. From now until I retire, my attention will stay precisely where it has always been: carrying out our strategy, meeting what we've promised shareholders and making sure leadership changes hands smoothly. My confidence in this organization's strength and its prospects has never been higher. I feel thankful to our employees, customers, shareholders and Board for giving me the chance to steer this company, and I'm eager to keep collaborating with the team throughout the months ahead; so with that, Brad, the floor is yours.
Brad Nagel
executiveThank you, Jim. Working alongside you and watching you lead the Electromed team these last few years has been a pleasure, and I'm glad we'll keep collaborating right up until the day you retire. Now, on to the numbers. Every figure I'm going to walk through covers the 12 months that closed on June 30, 2026 — I'll call that fiscal 2026 — and the comparison is against the 12 months that closed on June 30, 2025, or fiscal 2025, unless I say otherwise. Q4 net revenues rose 11.6%, reaching $19.4 million, which lifted net revenues for the whole of fiscal 2026 to a record $73.8 million, a gain of 15.3% over the $64 million posted a year earlier. In our direct home care market, annual revenues climbed 16.3% year-over-year, hitting $66.6 million versus $57.3 million in the prior year. That revenue growth came from more direct sales representatives, better productivity among those reps, and higher net revenues per approval. For fiscal year 2026, annualized home care revenue per weighted average direct sales representative came to $1,145,000, which is above Electromed's target range of $1 million to $1,100,000 per rep. Given how well we performed in fiscal 2026 and the efficiency gains we expect to continue in fiscal 2027, we are raising our fiscal year 2027 target range for home care revenue per rep to $1,050,000 to $1,150,000, as we weigh the record sales rep productivity from fiscal 2026 against the sales team expansion we have planned for fiscal 2027. Our non-home care business saw revenue rise 6.7% to $7.2 million in fiscal 2026. That gain was mainly driven by higher distributor and hospital revenue, which increased 12.7% and 9.6%, respectively. Gross profit came in at $57.9 million, or 78.5% of net revenues, up from $50 million, or 78.1% of net revenues, in fiscal 2025. The improvement in both gross profit and gross margin stemmed largely from higher revenue and greater net revenue per device. Selling, general and administrative, or SG&A, expenses totaled $42.7 million, which is $3.4 million more, or 8.7% higher, than $39.3 million. That rise was mostly attributable to greater salaries and incentive compensation tied to a higher average headcount across the sales, sales support, marketing and reimbursement teams, needed to handle more patient referrals. Operating income for the year reached $13.9 million, or 18.8% of net revenues, versus $9.7 million, or 15.1% of net revenues, a year ago. The 43.7% expansion in operating income shows the leverage we gained from mid-teen growth in net revenues and gross profit, offset by disciplined spending on the business' operating expenses, which rose roughly 9%. Taken together, these full year results let us celebrate a record year, with pretax income of $14.4 million, net income of $11.3 million, and full year EPS of $1.30 per diluted share. At June 30, 2026, Electromed held $20.5 million in cash and $29.8 million in accounts receivable, carried no debt, and reached working capital of $45.1 million with total shareholders' equity of $54 million. Our cash position shows growth of $5.2 million across the fiscal year that closed on June 30, 2026, whereas during the equivalent stretch a year earlier, cash declined by $0.8 million. For those 12 months ending June 30, 2026, the boost in cash came mainly from $9.7 million of positive operating cash flow, with stock buybacks of Electromed common shares amounting to $3.9 million acting as a partial offset. To wrap up, I want to say that Jim and I feel highly energized by how dedicated and committed the Electromed team has been as we keep delivering our cutting-edge SmartVest technology to patient groups that continue to be substantially underserved. Watching that commitment to the patients and physicians we support turn into such robust financial results during fiscal 2026 has been deeply gratifying, generating significant worth for Electromed and for our shareholders. Looking ahead to fiscal 2027, we still see chances to build on the investments already made in order to push our mission and our financial targets ahead, achieving double-digit top line growth, greater operating leverage and solid operating cash flow in the coming year. Operator, we're ready to take questions now.
Kyle Bauser
analystTo start with, Jim, congratulations on retiring next year — we're wishing you all the best.
Jim Cunniff
executiveI appreciate that, Kyle. Thank you.
Kyle Bauser
analystYes. I'm glad there's a little time available for the transition. So I appreciate the update on that. And perhaps as my first question, clearly it's been another very strong quarter in terms of operating leverage, and you touched on that somewhat; but could you perhaps talk a bit about what you expect regarding continued leverage in fiscal '27? And any plans to kind of bring on additional reps in territories too?
Jim Cunniff
executiveWell, as I believe Brad put it nicely, we don't think this year will necessarily be a repeat of the last fiscal year, but we definitely are projecting that we can achieve double-digit top line growth along with operating leverage. And that's the mantra we've been pounding the drum about for the last 3 years, and we've managed to deliver on it; so yes, we're confident that we can do so; we have brought on sales reps, which we're thrilled about; so as you heard during the prepared remarks, we truly finished the year with 64 direct sales reps. Many of them actually joined us, in June of the last fiscal year. But the great news is they were meant to help fill the gap for territory expansions that we have for this fiscal year. So we're sort of off to a fast start. That includes actually 2 hospital account liaisons. These are people that we're actually running a pilot with in a couple of key markets to see whether we can capture some of those patients who are in the hospital that subsequently get moved to the home and get those referrals. Beyond that, we also have 3 additional territories that we're aiming to fill. So touch wood, what we expect is to have 67 territories filled this year, including 2 hospital account liaisons. Brad also noted in his comments that we have increased our guidance on the revenue per rep for this year, though it's below where we finished last year. And that's primarily because, as you know, Kyle, some of these reps are going to need some time to ramp up and become productive for us. But yes, we're really bullish about the business and the new talent that we're adding to the team.
Kyle Bauser
analystUnderstood. Thanks for that. And for my follow-up question, it's clear the cash position keeps expanding while the share price has been really robust. Do you have any perspective on your approach to allocating capital and how you plan to put that cash to work moving forward?
Brad Nagel
executiveAppreciate the question, Kyle. The approach hasn't changed; when it comes to our cash, we still prioritize things in a certain order. Number one, reducing risk in the business. Number two, putting money back into the business. And like Jim said, we're bringing on a good number of sales reps as 2027 approaches and we want to back them up — not only the people, but also with the appropriate marketing resources, the appropriate spending on R&D, and to keep plowing money back into the business as much as we're able while still demonstrating leveraged growth throughout the P&L. Past that, just as we've done before, we'll keep seeking opportunities to boost shareholder value. Our primary approach for that has been share buybacks, something we've carried out over the last couple of years. So when the chance arises, we'll keep discovering ways to generate that shareholder value.
Arailym Kanatkyzy
analystPrior to asking what I wanted to ask, nice work on the news. 3 years and 15 straight quarters is a solid point to pass the baton. So thanks for accepting my question.
Jim Cunniff
executiveI appreciate the nice sentiment.
Arailym Kanatkyzy
analystMy first question concerns R&D. In percentage terms, spending rose significantly compared with the same period last year. It remains a modest line item on the P&L, though. Could you help us understand where that dollar is actually headed or will go? Is it refinement of the Clearway generator? Is it the data and connectivity aspect, things such as smart nodes? Or is it effort on something next to the existing platform?
Jim Cunniff
executiveExcellent question. As you noted, our R&D investment sits on a very small base. Ours is a one-product business. Consequently, when you examine our R&D spend, it truly splits into two parts for sustaining engineering. We are constantly considering how to improve the technology we currently have. That is one component of it. So we put money into that. The remaining portion is innovation. I believe I've brought this up during earlier calls previously. Among the areas where we feel somewhat more innovation is needed from our end — there are genuinely 2 such areas — one is connectivity, which we are addressing at this moment, just as you said; and the other component is simply broadening our vest line. To accomplish that mainly across the smaller sizes of our vest — that is genuinely where a major focus for our R&D team lies, namely to improve it and broaden it.
Arailym Kanatkyzy
analystThanks, and I have another question that ties in. In the deck, acquisitions appear as one of the 3 primary growth strategy pillars. I'd like to understand the specifics. When you mention inorganic opportunities, which problem are you aiming to fix? Is it bringing a second product to the reps who already carry one? Or is it gaining a capability such as monitoring data? Or does it come down to diversification?
Jim Cunniff
executiveYes, any of those could apply. No, I think those are excellent questions. So we're always evaluating — we are a company with a single product. It would be wonderful if we could give our sales reps another leg to the stool, put something in their bag that pairs with the call point they concentrate on and strengthens the customer relationship. And we're continuously watching for a situation where 1 plus 1 equals 3, that's interesting to us. We simply haven't discovered it yet; and to what you asked, we're not boxing ourselves into a single inorganic opportunity. If it works for our sales rep and it pairs with what they're doing, that's something we're very much open to. On the other hand, we've got a fantastic reimbursement team and contracting engine. And within the home care space, that's a highly valuable asset. So that's another area where we could see leveraging that capability through an acquisition and bringing somebody on board who may have a technology that fits this space, but they don't have that same type of capability.
Arailym Kanatkyzy
analystHonestly, I couldn’t be more thrilled about how things turned out.
Jim Cunniff
executiveI truly appreciate that.
Ben Haynor
analystTo start with, on my end, when I consider payer mix heading into fiscal 2027, it seems commercial declined by a couple of hundred basis points or so across fiscal '26. A portion of that is likely comps, while Medicare and Medicare Advantage ticked up slightly. What's the right way to view how that will track? Should we expect it to just fluctuate? Are there any fundamental trends pushing things in one direction or the other?
Jim Cunniff
executiveYeah. No, to begin, I appreciate the question, Ben, and I appreciate you joining the call. As you're aware, when we walk into a clinic and speak with a physician, we aren't determining which payer type the patient carries. What we're actually seeking is whether there are patients who might benefit from our technology. So from our vantage point, that's essentially a black box. We truly don't learn what kind of insurance that patient holds until a prescription has been written. So typically, and going back historically, the division has been fairly balanced between Medicare and commercial pay. I believe the positive news, and one point we want to emphasize, is that throughout the last fiscal year, we brought on 6 million additional covered lives. So previously, we might have received a prescription. We could have been out of network, and we're unable to fulfill it since the patient doesn't want to be saddled with a significant out-of-pocket cost. So through persistently expanding payer coverage, it only boosts our capacity to serve our patients and our capacity to no longer be out of network.
Ben Haynor
analystAll right. So aside from demographics, maybe, there isn't really an obvious pattern?
Jim Cunniff
executiveNo. What I'd say is, what does the figure show? Roughly 10,000 individuals daily reach age 65, I believe. That means the movement leans more in Medicare's direction. Still, looking back across the past 3 years, the division between Medicare and commercial pay has stayed essentially even, at 50 to 50.
Ben Haynor
analystOkay, that's clear. Then, my second point—regarding the CHEST guidelines, I think they came out fairly recently, and they list HFCWO broadly, if I'm not mistaken. How does that benefit your sales reps when they're out there detailing < >? Could you help us understand the way that assists people?
Jim Cunniff
executiveRight. What's encouraging, I'd say, is that no care guidelines have ever existed in the United States for treating bronchiectasis patients. Honestly, those guidelines will come out later in this quarter. So that has us enthusiastic; it's something we've anticipated for quite a while, Ben, as you're aware. It isn't as conclusive as we might hope. There's essentially no treatment algorithm for bronchiectasis patients. What the guidelines really highlight is a handful of various options a provider could employ to look after bronchiectasis patients; and airway clearance is among them, unsurprisingly. And as you heard during my remarks, these patients suffer from a chronic irreversible condition. Fluid accumulates in their lungs, and they require something to clear out that mucus, which serves as fuel for subsequent infections. So we're essentially the initial line of attack. Another item I'd direct your attention to—and this is thrilling—is that alongside the CHEST guidelines, the bronchiectasis and NTM Foundation have just rolled out a new BE care pathway. I believe that will help health care providers somewhat better grasp which tools are available in their toolbox for treating bronchiectasis patients. So it's encouraging for the industry overall, and it's encouraging for us since airway clearance appears in both of those guidelines.
Ben Haynor
analystWell done on the retirement — that's a great way to cap things off.
Jim Cunniff
executiveThanks, Ben, I really appreciate that.
Jim Cunniff
executiveYes, indeed. Thank you, operator. And prior to wrapping up this call, I'd like to share several important points regarding the quarter we just completed. To begin, we achieved our 15th straight quarter in which both revenue and profit rose compared with the same period a year earlier, setting records for revenue as well as diluted earnings per share. Delivering ongoing expansion and profitability is what we aim for. Consistent with that aim, we are putting money to work ahead of demand, for example by expanding our sales team. The chance presented by bronchiectasis is still considerable, and our Treat Smart from the Start campaign, alongside our efforts in clinical, educational and payer areas, are each intended to assist us in responsibly serving more patients. Our financial position is solid. Our balance sheet carries no debt, and we produce robust cash flow, both of which let us continue funding profitable growth. As ever, I appreciate your attendance today. Should you have any questions or wish to arrange a call with the Electromed team following today's report, kindly contact our Investor Relations partners at ICR Healthcare. Operator, please conclude the call.
Operator
operatorThat brings us to the end of today's teleconference. At this point, you're free to hang up your lines. We appreciate you joining us.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Electromed, Inc. transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Electromed, Inc. earnings transcripts and 131,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Electromed, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.